Instructions for Angelica (Estradiol, Drospirenone) 28 pills
Angelica (Estradiol, Drospirenone) 28 pills
English product name
Angelica®
Release form
Coated tablets
Description Angelica:
The tablets are covered with a film sheath of grey-pink color, round, double-convex, with the embossed "DL" in the correct hexagon on one side.
1 tab.
drospireno 2 mg
Estradiol (in the form of Estradiol hemihydrate) 1 mg
Auxiliary substances:
lactose monohydrate - 48.2 mg,
cornstarch - 14.4 mg,
cornstarch pregelatinized - 9.6 mg,
povidone K25 - 4 mg,
magnesium stearate - 0.8 mg,
hypromellose,
viscosity 5 sP - 1.0112 mg,
macrogol 6000 - 0.2024 mg,
talc - 0.2024 mg,
titanium dioxide - 0.5438 mg,
iron oxide red dye - 0.0402 mg.
28 pcs. - blister packs (1) with blister pockets - cardboard packs with first-opening control.
28 pcs. - blister packs (3) with blister pockets - cardboard packs with first-opening control.
ATC codes
G03FA17 Drospirenone and Estrogen
Clinical-pharmacological groups / Group affiliation
Anticlimacteric combined drug (estrogen+gestagen)
Active substance
Estradiol (in the form of hemihydrate)
drospireno
Pharmacotherapy group
Anti-climacteric agent combined (estrogen+gestagen)
Storage Conditions
The drug should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.
Best before date
Shelf life is 5 years. Do not apply after expiry date.
Method of use, course and dosage:
If a woman does not take estrogen or switches to Angelica® from another combination drug for continuous use, she can start treatment at any time.
Patients who switch to Angelica® with a combination drug for cyclic GST should start taking after the end of the current cycle of therapy.
Each package is designed for a 28-day reception.
You should take one tablet every day. After taking 28 tablets from the current package, the next day the new packaging of the drug Angelica® (continuous CGT) begins, taking the first tablet on the same day of the week as the first tablet from the previous package.
The tablet is swallowed whole, washed down with a small amount of liquid. The time of day when a woman takes the drug is irrelevant, but if she starts taking the pill at any given time, she should stick to that time and go on. The forgotten pill must be taken as soon as possible. If more than 24 hours have passed after the usual time of taking, no additional pill should be taken. If several tablets are missed, vaginal bleeding may develop.
The use of the drug is contraindicated in children and adolescents under 18 years of age.
Elderly patients: There is no evidence of dose correction in women under 65. When using Angelique® in women over 65 years of age, the information provided in the section "Dementia" of the section "Special Instructions" should be taken into account.
Testimony:
- hormone replacement therapy (HRT) of estrogen deficiency disorders in postmenopausal women with intact uterus,
- not earlier than 12 months after the last menstruation;
- prevention of osteoporosis in postmenopausal women with a high risk of fractures, with intolerance or contraindication to
- the use of other drugs for the prevention of osteoporosis
Application for kidney disorders
The use of the preparation in the case of severe kidney diseases is contraindicated at present or in anamnesis, acute renal insufficiency.
Use in liver disorders
The use of the preparation is contraindicated in the case of benign or malignant liver tumors (including anamnesis) and severe liver diseases.
Angelica® should be prescribed with care for congenital hyperbilirubinemia (Gilbert, Dubin-Johnson and Rotor syndromes), cholestatic jaundice or cholestatic itching. If liver function is impaired, DHT should be discontinued.
Terms of Sale
The drug is prescription.
Application in elderly patients
There is no evidence of dose correction in women under 65.
There is evidence of an increased risk of dementia in women starting combination or monotherapy for DHT over the age of 65.
Use in children
The use of the preparation in children and adolescents under 18 years of age is contraindicated.
- Nosology Estradiol (ICD codes)
- M80.0
- Postmenopausal osteoporosis with pathological fracture
- M80.1
- Osteoporosis with pathological fracture after ovarian removal
- M81.0
- Postmenopausal osteoporosis
- M81.1
- Osteoporosis after ovarian removal
- N95.1
- Menopause and Menopause in Women
- N95.3
- Conditions associated with artificially induced menopause
pharmachologic effect:
The drug Angelica® contains 17β Estradiol, chemically and biologically identical to human endogenous estradiol, and a synthetic progestogen, drospirenone. 17β-Estradiol provides estrogen replacement in the female body during and after menopause. The addition of drospirenone provides control over bleeding and prevents the development of estrogen-induced endometrial hyperplasia.
